CJC-1295

Description

CJC-1295 (without DAC) is a synthetic analogue of growth hormone–releasing hormone, specifically the 1–29 amino acid fragment that retains the receptor-binding region of the parent molecule. The peptide is produced through solid-phase synthesis and incorporates targeted substitutions designed to extend its in-vitro stability and resist enzymatic cleavage at common degradation sites.

Within the cellular environment, CJC-1295 acts on the GHRH receptor expressed on somatotroph cells, where it can be examined for its capacity to influence pulsatile growth hormone signalling. Researchers commonly use the peptide as a probe in models of anterior-pituitary biology, receptor pharmacology, and downstream IGF-1 pathway activation, both in isolation and in combination with secretagogue analogues such as ipamorelin.

Applications in research include in-vitro assays exploring GHRH receptor binding kinetics, ex-vivo investigations of pituitary cell signalling, comparative work on long-acting versus short-acting GHRH analogues, and structural studies probing the relationship between sequence modification and peptide half-life.

This product is supplied as a lyophilised powder for laboratory use only. Not intended for human or veterinary use, diagnosis, or treatment. Purchasers must be 18 or older and confirm intended research application.